Thomas Kerbusch
President at Certara Strategic Consulting
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Richard Traynor | M | 53 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
William Feehery | M | 54 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | 5 years |
Michael Schemick | M | 50 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
Richard James Wilson | M | 53 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Kerbusch
- Personal Network